- Home
- RHLD vs NGNE Comparison
RHLD vs NGNE Comparison
Compare RHLD & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHLD
- NGNE
- Stock Information
- Founded
- RHLD 2024
- NGNE 2003
- Country
- RHLD United States
- NGNE United States
- Employees
- RHLD N/A
- NGNE N/A
- Industry
- RHLD
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- RHLD
- NGNE Health Care
- Exchange
- RHLD NYSE
- NGNE Nasdaq
- Market Cap
- RHLD 217.1M
- NGNE 213.2M
- IPO Year
- RHLD N/A
- NGNE N/A
- Fundamental
- Price
- RHLD $37.22
- NGNE $21.94
- Analyst Decision
- RHLD
- NGNE Strong Buy
- Analyst Count
- RHLD 0
- NGNE 7
- Target Price
- RHLD N/A
- NGNE $41.86
- AVG Volume (30 Days)
- RHLD 100.9K
- NGNE 222.5K
- Earning Date
- RHLD 08-15-2025
- NGNE 08-08-2025
- Dividend Yield
- RHLD N/A
- NGNE N/A
- EPS Growth
- RHLD N/A
- NGNE N/A
- EPS
- RHLD 12.54
- NGNE N/A
- Revenue
- RHLD $420,450,000.00
- NGNE $925,000.00
- Revenue This Year
- RHLD N/A
- NGNE N/A
- Revenue Next Year
- RHLD N/A
- NGNE N/A
- P/E Ratio
- RHLD $3.18
- NGNE N/A
- Revenue Growth
- RHLD 11.09
- NGNE N/A
- 52 Week Low
- RHLD $24.22
- NGNE $6.88
- 52 Week High
- RHLD $54.05
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- RHLD N/A
- NGNE 62.83
- Support Level
- RHLD N/A
- NGNE $19.01
- Resistance Level
- RHLD N/A
- NGNE $18.21
- Average True Range (ATR)
- RHLD 0.00
- NGNE 1.65
- MACD
- RHLD 0.00
- NGNE 0.41
- Stochastic Oscillator
- RHLD 0.00
- NGNE 96.68
About RHLD RESOLUTE HOLDINGS MANAGEMENT INC
Resolute Holdings Management Inc is provide operating management services. The company has two operating segments and two reportable segments: Payment Card and Arculus. Payment Card generates its revenue through the production and sale of metal payment cards while Arculus generates its revenue through the production and sale of metal payment or nonpayment cards containing Arculus technology for authentication and/or digital asset cold storage and related services. The company generates maximum revenue Domestically.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.